Genpharmasec Ltd Financials
Company Logo

Genpharmasec Ltd Financial Statement

Genpharmasec Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue5.88
Operating Expense5.07
Net Profit0.59
Net Profit Margin10.03
Earning Per Share0.01
EBIDTA0.66
Effective Tax RateTBA

Genpharmasec Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual30.41
Operating Expenses Annual30.25
Operating Profit Annual0.88
Interest Annual0.39
Depreciation0.02
Net Profit Annual0.05
Tax Annual0.42

Genpharmasec Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning1.99
Cash Flow from Operations-2.27
Cash Flow from Investing-29.03
Cash Flow from Financing47.89
Cash Flow at the End18.58

Genpharmasec Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)2.86
PBIT Margin (%)2.80
PBT Margin (%)-4.47
Net PROFIT Margin (%)0.16
Return On Networth / Equity (%)0.11
Return On Networth /Employed (%)1.81
Return On Assets (%)0.12
Total Debt / Equity (X)0.08
Asset Turnover Ratio (%)0.71

Genpharmasec Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.10
Total Current Assets Annual40.04
Non Current Assets Annual30.44
Total Shareholders Funds Annual64.57
Total Assets Annual70.47

Genpharmasec Ltd Earning Calls

EPS (INR)

Expected

0.01

Reported

0.01

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Mar 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Sep 19, 2024, Genpharmasec Ltd has a market capitalization of 123.48 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Genpharmasec Ltd is debt-free with a debt-to-equity ratio of 0.05.
In FY 2023 , Genpharmasec Ltd recorded a total revenue of approximately 30.41 Cr marking a significant milestone in the company's financial performance.
Genpharmasec Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.1% annually, respectively..
Genpharmasec Ltd's current PE ratio is 2469.60.
Genpharmasec Ltd's ROCE averaged 0.1% from the FY ending March 2022 to 2024, with a median of 1.3%. It peaked at 1.8% in March 2023, reflecting strong capital efficiency over the period..
Genpharmasec Ltd's latest EBIT is Rs. 0.86 Cr, surpassing the average EBIT of Rs. 0.25 Cr over the 5 years..